Twilio (NYSE:TWLO) launched a HIPAA-eligible customer data platform within its Healthcare & Life Sciences segment. The platform aims at improving patients’ experiences as well as health outcomes.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Twilio provides a cloud communications platform that allows software developers to programmatically make and receive phone calls, text messages, and perform other communication functions using its web service APIs (Application Programming Interfaces).
According to the company, the customer data platform will help any healthcare organization to transcend to relationship-based care from a transactional-based approach. Healthcare organizations will be able to collect insights across all of the patient’s data to streamline processes, thereby creating better patient engagement, and improving health outcomes on a larger scale.
Sandip Chandarana, AVP of Application Development at Healthfirst, commented, “With Twilio Segment’s HIPAA-eligible CDP and Twilio’s programmable contact center, Flex, we can offer more customized care options, proactively connect with patients for preventive care and real-time assistance, and build specific features derived by members’ customer data that can improve their experience and health outcomes.”
Is TWLO a Buy or Sell?
As per TipRanks, analysts are cautiously optimistic about the Twilio stock and have a Moderate Buy consensus rating, which is based on 15 Buys and nine Holds. Twilio’s average price forecast of $84.04 implies 59.05% upside potential.
Concluding Thoughts
Twilio stock has lost 80% of its market capitalization over the past year. In fact, it is trading well below its all-time high of $350 seen in 2021. The stock took a further downward slide after the company reported a weak Q4 outlook despite better-than-expected Q3 results on November 3.
At Enterprise Value/Revenue of 2x, the current valuations look cheap compared to its high historical average of more than 30x. Perhaps, investors will wait for some signs of recovery before adding positions to the stock.
Read full Disclosure
